Result of Annual General Meeting

Medica Group PLC

30 June 2023

 

30 June 2023

Medica Group Plc

Result of Annual General Meeting

Medica Group PLC (LSE:MGP, "Medica" or the "Company"), an international provider of high-quality telemedicine services, announces that, at its Annual General Meeting held at 10.30am today at the offices of DLA Piper, 160 Aldersgate Street, London EC1A 4HT, all resolutions put to the meeting were duly passed.

Details of the voting are as follows:

Resolution		For/ Discretion (Number of votes)	% For/ Discretion	Against (Number of votes)	% Against	Total votes	Withheld (Number of votes)
Ordinary Business
Ordinary Resolutions
1.	To receive and adopt the annual report, accounts and the auditor's report	66,479,561	100.00	0	0.00	66,479,561	249,911
2.	To approve the Directors' Remuneration Report	37,121,768	57.83	27,067,040	42.17	64,188,808	2,540,664
3.	To declare a final dividend	See note below*
4.	To re-appoint Grant Thornton UK LLP as auditors	66,081,401	99.40	399,054	0.60	66,480,455	249,017
5.	To authorise the Directors to determine the remuneration of the auditors	66,716,249	99.98	10,759	0.02	66,727,008	2,464
6.	To re-elect Roy Davis as a Director	65,870,471	99.21	526,381	0.79	66,396,852	332,620
7.	To re-elect Barbara Moorhouse as a Director	66,204,304	99.22	522,538	0.78	66,726,842	2,630
8.	To re-elect Joanne Easton as a Director	66,204,415	99.21	524,189	0.79	66,728,604	868
9.	To re-elect Dr Junaid Bajwa as a Director	65,093,295	97.92	1,384,696	2.08	66,477,991	251,481
10.	To re-elect Stuart Quin as a Director	66,726,029	100.00	813	0.00	66,726,842	2,630
11.	To re-elect Richard Jones as a Director	66,477,880	100.00	111	0.00	66,477,991	251,481
Special Business
Ordinary resolution
12.	General authority to allot shares pursuant to Section 551 Companies Act 2006	66,717,902	99.99	8,940	0.01	66,726,842	2,630
Special resolutions
13.	Standard pre-emption disapplication	64,925,423	97.30	1,800,717	2.70	66,726,140	3,332
14.	Additional pre-emption disapplication for the purpose of financing an acquisition or other capital investment	64,672,763	96.92	2,053,377	3.08	66,726,140	3,332
15.	Authority to make market purchases of up to 12,288,363 shares	65,844,437	99.62	248,149	0.38	66,092,586	636,886
16.	To authorise general meetings to be held on 14 clear days' notice	66,165,995	99.16	562,609	0.84	66,728,604	868

* As previously communicated by an RNS announcement this morning, the resolution to declare a final dividend for the year ended 31 December 2022 of 1.88 pence per share ("2022 Final Dividend") (Resolution 3) was withdrawn prior to, and was not presented to, the AGM. This will ensure shareholders receive 212 pence per share in full without any reduction in respect of the previously proposed 2022 Final Dividend as opposed to two separate payments and in accordance with the terms of the recommended cash acquisition for the Company by Moonlight Bidco Limited (once effected).

For further information, please contact:

Medica Group Plc: Stuart Quin, Chief Executive Officer Richard Jones, Chief Financial Officer	[phone]
FTI Consulting Victoria Foster Mitchell Sam Purewal	[phone]
Liberum (Joint Broker) Phil Walker Richard Lindley	[phone]
Numis (Joint Broker) Freddie Barnfield Duncan Monteith Euan Brown	[phone]

About Medica Group PLC

Medica (LSE:MGP) is an international provider of high-quality telemedicine services. It is the market leader in teleradiology in the UK and Ireland, working with more than 100 NHS Trusts and HSE hospitals in Ireland, in addition to private hospitals, insurance groups and diagnostic imaging companies. Its network of consultant radiologists, radiographers and specialist doctors interpret and report MRI, CT, ultrasound and X-ray images on behalf of healthcare providers, using Medica's bespoke, secure technology platform for fast and responsive delivery. The company's core services include NightHawk, an urgent, out-of-hours offering available to clients 24/7 with dedicated pathways for stroke and major trauma, and Elective, for routine reporting.

In Ireland, Medica carries out patient scanning, as well as reporting, and runs a diabetic retinopathy screening programme for the National Screening Service. Through its US business, RadMD, Medica provides global pharmaceutical and biotech companies, as well as contract research organisations with specialist imaging services for clinical trials.

For more information please visit: www.medicagroupplc.com 

 

END